Specialty pharma firm Antares Pharma (ATRS) pared down its losses in the fourth quarter due to reduced R&D expenses. The company reported a loss of $3.7 million or $0.02 per share compared to $4.4 million or $0.03 per share in the prior year period. Sales declined marginally by 1% to $14 million.
On the products front, OTREXUP sales improved 17% to $4.8 million and auto injector devices sales more than doubled to $3.1 million. Development revenues decreased to $2.2 million as products under development is getting ready for market launch. With its partner AMAG Pharmaceuticals’ Makena product getting FDA approval, the company expects its top line to improve in 2018 as AMAG uses Antares’ QuickShot auto injector.
For fiscal 2017, sales improved 4% to $54.5 million, while net loss reduced to $16.7 million compared to $24.2 million, helped by reduced expenses.
Most Popular
PNC Earnings: A snapshot of PNC Financial Services’ Q4 2025 results
PNC Financial Services Group, Inc. (NYSE: PNC) on Friday reported higher revenue and net income for the fourth quarter of fiscal 2025. The numbers also beat analysts' estimates. Total revenues
Earnings Preview: Intuitive Surgical (ISRG) looks poised for a strong Q4
Intuitive Surgical, Inc. (NASDAQ: ISRG) is a pioneer in robotic-assisted surgical technology, developing advanced systems that enable healthcare professionals to perform minimally invasive procedures with greater precision and efficiency. Having
What to expect when Alaska Air Group (ALK) reports Q4 2025 earnings results
Shares of Alaska Air Group (NYSE: ALK) gained 3% on Thursday. The stock has dropped 26% in the past 12 months. The airline is scheduled to publish its earnings results
